arrow
C

Camilla Nero

university of naples federico ii
H指数:26
被引数:1,804

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline pathogenic variants identification through comprehensive cancer genome profiling

通过全面癌症基因组分析鉴定生殖系致病性变异

2026-10-270
OAAI
Enhanced Detection of BRCA Copy Number Alterations Within a Commercial HRD Assay: Implications for Precision Oncology in Ovarian Cancer

BRCA拷贝数改变在商业HRD检测中的增强检测:对卵巢癌精准肿瘤学的意义

2026-04-290
OAAI
Developing and validating ultrasound-based machine-learning models incorporating radiomics features to predict malignancy in adnexal masses

开发和验证基于超声的机器学习模型,整合放射组学特征以预测附件肿块的恶性程度

2026-03-300
OAAI
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions

液体活检在非转移性前列腺癌中的应用:临床证据与未来方向

Cancers
IF4.4
2026-03-010
OAAI
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026-01-010
PRE
Electronic Nose-Based Volatile Organic Compound Profiling in Gynecologic Oncology: Current Evidence and Diagnostic Accuracy

基于电子鼻的挥发性有机化合物在妇科肿瘤学中的特征分析:当前证据与诊断准确性

2025-12-160
OAAI
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease

非转移性前列腺癌的新型综合基因组图谱分析:使用FPG500检测代表疾病进展的可操作突变的研究方案

2025-10-100
PRE
Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study

临床意义显著BRCA大基因组重排的检测:一项比较NGS研究(在FFPE卵巢癌样本中)

2025-10-010
OAAI
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer

根据分子靶点临床可操作性量表(ESCAT)评估的,无特定分子特征(NSMP)子宫内膜癌的基因可操作性

2025-09-030
OAAI
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib

NRG1变异体不确定意义(VUSes)在晚期非小细胞肺癌中的网络分析及其在EGFR突变患者接受一线奥希替尼治疗中的预后作用

2025-08-290
OAAI
A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer

肿瘤标志物的比较分析显示EDA纤维连接蛋白是高级别浆液性卵巢癌的一个有希望的治疗靶点。

2025-08-280
OAAI
Image-guided real-time optical biopsy in oncologic surgery: a systematic review of the role of confocal microscopy in the era of digital surgery

影像引导的实时光学活检在肿瘤手术中的应用:数字手术时代共聚焦显微镜作用的系统综述

2025-08-250
OAAI
Focal lymphovascular space invasion: friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas

病灶淋巴血管间隙浸润:益友还是祸患?一项关于Ⅰ期子宫内膜样子宫内膜癌的大规模回顾性分析

2025-08-200
PREAI
ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study

ENCODESTRO评分:黑暗面在哪里?子宫内膜癌分子分型中雌激素受体表达截断值的评估,一项回顾与前瞻性结合研究

2025-08-050
PRE
Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision Medicine

肾细胞癌中的多组学:精准医学的当前格局和未来方向

2025-05-260
OA
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据BRCA1/2突变类型和位点,在新诊断卵巢癌患者中从PARP抑制剂维持治疗中获益:一项多中心真实世界研究

2025-04-011
OAAI